Back to search results

Rimegepant for Trigger-Induced Migraine Prevention

This study is looking at whether rimegepant 75 mg can help prevent migraine attacks when taken before a known trigger. You might be able to join if you are an adult (18 or older) with a history of episodic migraine for at least one year, experiencing 2-8 moderate to severe migraines per month, and have reliable migraine triggers like exercise, alcohol, air travel, sexual activity, fasting, or stress. The researchers want to see what percentage of the time rimegepant prevents a moderate to severe headache within 24 hours of taking the dose. This study is currently unclear on its recruitment status and plans to enroll 60 participants.

Study design
This is a single-center, open-label study, meaning both you and the study staff will know you are receiving rimegepant. It plans to include 60 adult participants.
What's involved
You would take rimegepant 75 mg two hours before a known migraine trigger. The study will measure headache intensity 24 hours after you take the dose.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 24 hours post-dose, which suggests a short-term follow-up for each treatment instance.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07301008

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Recruiting
PHASE4Ages 18+InterventionalPrevention
Medstar Health Research Institute
~60 participants
Updated 2025-12-24 on ClinicalTrials.gov
What's tested:Rimegepant 75 MG

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity
Measured over 24 hour post dose

Conditions

Migraine
Trigger Induced Migraine

Explore related trials

Migraine

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Jessica Ailani, MD · PRINCIPAL_INVESTIGATOR · MedStar's Georgetown University Hospital

Who to contact

Yemisrach Tadesse
[email protected]
3015708508
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders-3 (ICHD-3)
Men and women ≥ 18 years old .
Average of 2-8 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the screening visit
Headache/migraine onset before age 50 years
Migraine attacks, on average, lasting 4-72 hours if untreated
At least 48 hours between migraine attacks
Ability to distinguish migraine attacks from tension or cluster headaches
Particpants on SOC treatment should be on stable regimen for at least 3 months prior to enrollment and should not change their regimen during the course of the study
Participant may have been on treatment with Botox or mAbs for the last 6 months
Participants experience migraine ≥75% of the time following exposure to a trigger during the run-in period. Acceptable triggers include exercise, alcohol ( less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or weekend/ let-down

Exclusion

Using gepants as preventive treatment (atogepant once daily (QD) or rimegepant every other day (EOD)), or using zavegepant or ubrogepant as an acute treatment
History of use of narcotic or barbiturate containing medications, including opioids (e.g., morphine, codeine, oxycodone, and hydrocodone) on ≥5 days per month on a regular basis for ≥3 months prior to screening
Current evidence of uncontrolled, unstable, or recently diagnosed cardiovascular disease, uncontrolled hypertension, or uncontrolled diabetes.
Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder.
Women must not be pregnant, lactating or breastfeeding

What this trial measures

  • Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity24 hour post dose

    Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity occurs within 24 hours